| Date Filed | Type | Description |
| 08/21/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/21/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 06/08/2023 |
4
| Clowes Howard (Director) has filed a Form 4 on PLUS THERAPEUTICS, INC.|
Txns:
| Bought 1,000 shares
@ $3.98, valued at
$4k
|
|
| 05/16/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements AUSTIN, Texas, May 16, 2023 - Plus Therapeutics, Inc. , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that it has received notification from The Nasdaq Stock Market LLC that the staff has determined that for the last 10 consecutive business days, from May 1, 2023 to May 12, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Therefore, the Company has regained compliance with Listing Rule 5550. Accordingly, Nasdaq has advised that the matter is now closed. About Plus Therapeutics Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing t..." |
|
| 05/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/28/2023 |
8-K
| Quarterly results |
| 04/21/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/07/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/06/2023 |
4
| Hawkins Richard J (Director) has filed a Form 4 on PLUS THERAPEUTICS, INC.|
Txns:
| Bought 1 preferred shares
@ $1000, valued at
$1k
|
|
| 02/24/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 02/23/2023 |
8-K
| Quarterly results |
| 02/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/04/2023 |
4
| Lenk Robert P (Director) has filed a Form 4 on PLUS THERAPEUTICS, INC.|
Txns:
| Sold 1,500 shares
@ $0.3147, valued at
$472.1 |
|
| 12/15/2022 |
8-K
| Quarterly results |
| 11/28/2022 |
8-K
| Quarterly results |
| 10/20/2022 |
8-K
| Quarterly results |
| 10/20/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/22/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 09/09/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 09/09/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/18/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/17/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/17/2022 |
8-K
| Other Events Interactive Data |
| 08/08/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 08/08/2022 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu... |
| 07/21/2022 |
8-K
| Quarterly results |
| 07/21/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|